Suppr超能文献

血清CA 125、癌胚抗原和CA 19-9作为卵巢交界性肿瘤的肿瘤标志物。

Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.

作者信息

Engelen M J, de Bruijn H W, Hollema H, ten Hoor K A, Willemse P H, Aalders J G, van der Zee A G

机构信息

Division of Gynecologic Oncology, University Hospital Groningen, The Netherlands.

出版信息

Gynecol Oncol. 2000 Jul;78(1):16-20. doi: 10.1006/gyno.2000.5811.

Abstract

OBJECTIVES

The goals of this study were to analyze preoperative serum levels of CA 125, carcinoembryonic antigen (CEA), and CA 19-9 in patients with borderline ovarian tumors and to investigate if routine assessment of these markers in follow-up may lead to earlier detection of recurrence.

METHODS

For patient identification a database was used, in which data from all patients treated for gynecologic malignancies in the Department of Gynecologic Oncology, University Hospital Groningen, The Netherlands, are compiled. Between 1982 and 1997, 44 patients with borderline ovarian tumors were identified. Clinical data and serum CA-125 and CEA levels were retrieved from the database. CA 19-9 levels were determined in retrospect in available stored preoperative (24 patients) and follow-up (43 patients) serum samples.

RESULTS

Preoperative CA 125 levels were elevated in 8 of 33 (24%), CEA levels in 3 of 32 (9%), and CA 19-9 levels in 11 of 24 (46%) cases. In patients with mucinous tumors preoperative CA 19-9 was more frequently elevated (8/14, 57%) than CA 125 (3/20, 15%) (P = 0.02) or CEA (2/18, 11%) (P = 0.02). Complete follow-up serum CA 125, CEA, and CA 19-9 levels were available for 43 of 44 patients. Median follow-up was 84 months (range, 22-204). During follow-up two patients (5%) had recurrent disease. In one patient CA 125 became elevated at the time of recurrence; in the other patient (in retrospect) the CA 19-9 level did not return to normal after surgery, but kept rising, preceding clinical symptoms of recurrence for 13 months.

CONCLUSIONS

If one chooses to use serum markers in follow-up of mucinous borderline ovarian tumors CA 19-9 should be included. Measurement of serum tumor markers in the follow-up of patients with borderline ovarian tumors may lead to earlier detection of recurrence in only a very small proportion of patients, while the clinical value of earlier detection of recurrence remains to be established.

摘要

目的

本研究的目的是分析卵巢交界性肿瘤患者术前血清CA 125、癌胚抗原(CEA)和CA 19-9水平,并探讨在随访中常规检测这些标志物是否能更早发现复发。

方法

通过使用一个数据库来识别患者,该数据库汇总了荷兰格罗宁根大学医学中心妇科肿瘤学部门治疗的所有妇科恶性肿瘤患者的数据。1982年至1997年间,共识别出44例卵巢交界性肿瘤患者。从数据库中检索临床数据以及血清CA-125和CEA水平。对可用的术前(24例患者)和随访(43例患者)储存血清样本进行回顾性测定CA 19-9水平。

结果

33例患者中有8例(24%)术前CA 125水平升高,32例中有3例(9%)CEA水平升高,24例中有11例(46%)CA 19-9水平升高。在黏液性肿瘤患者中,术前CA 19-9升高的频率(8/14,57%)高于CA 125(3/20,15%)(P = 0.02)或CEA(2/18,11%)(P = 0.02)。44例患者中有43例可获得完整的随访血清CA 125、CEA和CA 19-9水平。中位随访时间为84个月(范围22 - 204个月)。随访期间,2例患者(5%)出现疾病复发。1例患者复发时CA 125升高;另1例患者(回顾性分析)术后CA 19-9水平未恢复正常,而是持续升高,比复发的临床症状早13个月。

结论

如果选择在黏液性卵巢交界性肿瘤随访中使用血清标志物,应包括CA 19-9。在卵巢交界性肿瘤患者随访中检测血清肿瘤标志物仅在极少数患者中可能导致更早发现复发,而更早发现复发的临床价值仍有待确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验